Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Drugs Made In America Acquisition Corp. ( (DMAA) ) is now available.
On April 7, 2026, Drugs Made in America Acquisition Corp. signed a letter of intent with Power Analytics Global Corp., a Delaware-based company, to pursue a de-SPAC transaction that would result in Power Analytics becoming a publicly traded company. The prospective deal, which remains subject to negotiation and a definitive business combination agreement, contemplates an indicative valuation of about $1.0 billion for Power Analytics, adjustable based on due diligence findings, capital structure, net debt, working capital and prevailing market conditions.
This proposed de-SPAC transaction marks a significant potential milestone in converting Power Analytics Global Corp. into a public entity while advancing the SPAC’s mandate to complete a qualifying business combination. The contemplated valuation and adjustment framework underscore the importance of financial and operational vetting, signaling that final terms could materially affect the economics and ownership outcomes for both parties and their stakeholders as the process moves forward.
More about Drugs Made In America Acquisition Corp.
Drugs Made in America Acquisition Corp. is a special purpose acquisition company focused on identifying and merging with operating businesses to take them public. It operates as a blank-check entity, raising capital on public markets with the aim of completing a business combination that provides its chosen target with a streamlined route to public listing.
Average Trading Volume: 91,273
Technical Sentiment Signal: Strong Buy
Current Market Cap: $352.3M
See more data about DMAA stock on TipRanks’ Stock Analysis page.